Wedbush Reiterates Outperform on Cartesian Therapeutics, Maintains $38 Price Target
Wedbush analyst Martin Fan reiterates Cartesian Therapeutics (NASDAQ:RNAC) with a Outperform and maintains $38 price target.
Read original at benzingaStocks · News reference
New Partnership Gives Cartesian Therapeutics Another Shot At Autoimmune Disease Market
Cartesian Therapeutics gains after licensing an in vivo CAR-T platform from WestGene, with a myasthenia gravis trial planned for 2026.
Reference details
Connected markets
Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.
- Source
- benzinga
- Observed
- Jun 9, 2026, 5:31 PM
- Checked
- Jun 9, 2026, 5:35 PM
- Cadence
- Captured once, then retained as an archive reference
- Status
- fresh
Keep reading
Related headlines
Cartesian Therapeutics Q2 EPS $0.46 Beats $(0.86) Estimate
Cartesian Therapeutics (NASDAQ:RNAC) reported quarterly earnings of $0.46 per share which beat the analyst consensus estimate of $(0.86) by 153.49 percent. This is a 8 percent decrease over earnings of $0.50 per share
Read original at benzinga8-K filing — Cartesian Therapeutics, Inc. (RNAC)
Filed: 2026-08-06 AccNo: 0001453687-26-000100 Size: 1 MB Item 2.02: Results of Operations and Financial Condition Item 9.01: Financial Statements and Exhibits
Read original at edgar